Edwards Lifesciences Corporation


SKU: EW-1 Category:


Edwards Lifesciences Corporation managed to exceed analyst expectations in terms of revenue as well as earnings. It achieved double-digit sales growth in the quarter driven by increased adoption of its innovative therapies. The total sales increased. In TAVR, Edwards continues to view strong demand for its leading SAPIEN platform. The second quarter TAVR sales were helped by improved hospital staffing levels as well as the continued successful launch of the SAPIEN 3 Ultra RESILIA. Outside the U.S., the company had positive sales growth from all regions. The sales growth in Europe was driven by a broad-based adoption of its SAPIEN platform. In Japan, the sales grew. TMTT’s second-quarter worldwide sales increased. Growth was driven by continued robust overall procedure volumes, activation of more centers across Europe and the U.S., and adoption of its differentiated PASCAL Precision platform. In tricuspid, with PASCAL, the Class IITR pivotal trial continues enrolling well. In Surgical, sales of the quarter increased driven by the adoption of its premium RESILIA products across every region. In Critical Care, sales increased. Sales momentum for its HemoSphere monitoring platform was positive. We give Edwards Lifesciences Corporation a ‘Hold’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!